Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Briasoulis, Evangelos; Karavasilis, Vasilios; Tzamakou, Eleftheria; Rammou, Dimitra; Soulti, Kali; Piperidou, Christina; Pavlidis, Nicholas

doi:10.1007/s00280-003-0750-5

Cited by 44 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delays in clearance of PLD have been observed clinically when PLD was combined with taxanes (46)(47)(48). Cyclophosphamide, particularly at high doses, is known to have also immunologic effects and therefore could alter the pharmacokinetics of subsequently administered agents.…”

Section: Discussionmentioning

confidence: 99%

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Geretti

Leonard

Dumont

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Given the bulky nature of nanotherapeutics relative to small molecules, it is hypothesized that effective tumor delivery and penetration are critical barriers to their clinical activity. HER2-targeted PEGylated liposomal doxorubicin (MM-302, HER2-tPLD) is an antibody-liposomal drug conjugate designed to deliver doxorubicin to HER2-overexpressing cancer cells while limiting uptake into nontarget cells. In this work, we demonstrate that the administration and appropriate dose sequencing of cyclophosphamide can improve subsequent MM-302 delivery and enhance antitumor activity in preclinical models without negatively affecting nontarget tissues, such as the heart and skin. We demonstrate that this effect is critically dependent on the timing of cyclophosphamide administration. Furthermore, the effect was found to be unique to cyclophosphamide and related analogues, and not shared by other agents, such as taxanes or eribulin, under the conditions examined. Analysis of the cyclophosphamide-treated tumors suggests that the mechanism for improved MM-302 delivery involves the induction of tumor cell apoptosis, reduction of overall tumor cell density, substantial lowering of interstitial fluid pressure, and increasing vascular perfusion. The novel dosing strategy for cyclophosphamide described herein is readily translatable to standard clinical regimens, represents a potentially significant advance in addressing the drug delivery challenge, and may have broad applicability for nanomedicines. This work formed the basis for clinical evaluation of cyclophosphamide for improving liposome deposition as part of an ongoing phase I clinical trial of MM-302 in HER2-positive metastatic breast cancer. Mol Cancer Ther; 14(9); 2060-71. Ó2015 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Geretti

Leonard

Dumont

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…DOXIL/Caelyx is now undergoing trials for treatment of other malignancies such as multiple myeloma (Hussein and Anderson 2004), breast cancer (Robert et al 2004), and recurrent high-grade glioma (Hau et al 2004). Several studies are under way to investigate the anticancer activities of PLD in combination with other therapeutics, including the taxanes (paclitaxel or docetaxel) (Briasoulis et al 2004; Vorobiof et al 2004), temozolomide (Temodal ® Schering-Plough, Kenilworth, NJ, USA) (Awada et al 2004), and vinorelbine (Katsaros et al 2005). …”

Section: Long-circulating Liposomesmentioning

confidence: 99%

New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?

2006

View full text Add to dashboard Cite

Among several promising new drug-delivery systems, liposomes represent an advanced technology to deliver active molecules to the site of action, and at present several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles (“first-generation liposomes”) to “second-generation liposomes”, in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. A significant step in the development of long-circulating liposomes came with inclusion of the synthetic polymer poly-(ethylene glycol) (PEG) in liposome composition. The presence of PEG on the surface of the liposomal carrier has been shown to extend blood-circulation time while reducing mononuclear phagocyte system uptake (stealth liposomes). This technology has resulted in a large number of liposome formulations encapsulating active molecules, with high target efficiency and activity. Further, by synthetic modification of the terminal PEG molecule, stealth liposomes can be actively targeted with monoclonal antibodies or ligands. This review focuses on stealth technology and summarizes pre-clinical and clinical data relating to the principal liposome formulations; it also discusses emerging trends of this promising technology.

show abstract

“…Recent clinical studies have demonstrated higher effectiveness of multiple drug delivery compared to single drug administration, eg, in cancer therapy. 72,73 However, blended or bilayered particles loaded with multiple drugs do not allow control of individual drug release. 74 Several techniques, such as microfluidic techniques and layerby-layer self-assembly and emulsion, were suggested to enable separate regulation of multiple drug-release kinetics.…”

Section: Coaxial Electrosprayingmentioning

confidence: 99%

Advances in drug delivery via electrospun and electrosprayed nanomaterials

Zamani¹,

Prabhakaran²,

Ramakrishna³

2013

IJN

202

104

View full text Add to dashboard Cite

Electrohydrodynamic (EHD) techniques refer to procedures that utilize electrostatic forces to fabricate fibers or particles of different shapes with sizes in the nano-range to a few microns through electrically charged fluid jet. Employing different techniques, such as blending, surface modification, and coaxial process, there is a great possibility of incorporating bioactive such molecules as drugs, DNA, and growth factors into the nanostructures fabricated via EHD techniques. By careful selection of materials and processing conditions, desired encapsulation efficiency as well as preserved bioactivity of the therapeutic agents can be achieved. The drug-loaded nanostructures produced can be applied via different routes, such as implantation, injection, and topical or oral administration for a wide range of disease treatment. Taking advantage of the recent developments in EHD techniques like the coaxial process or multilayered structures, individually controlled delivery of multiple drugs is achievable, which is of great demand in cancer therapy and growth-factor delivery. This review summarizes the most recent techniques and postmodification methods to fabricate electrospun nanofibers and electrosprayed particles for drug-delivery applications.

show abstract

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Cited by 44 publications

References 28 publications

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?

Advances in drug delivery via electrospun and electrosprayed nanomaterials

Contact Info

Product

Resources

About